Alerta

一种ROS响应型抗肿瘤苯硼酸酯纳米药物及其制备方法和应用

Resumen de: CN120884715A

本发明属于生物医用高分子材料领域，涉及一种ROS响应型抗肿瘤苯硼酸酯纳米药物及其制备方法和应用。所述ROS响应型抗肿瘤苯硼酸酯纳米药物为将两亲性聚合物前药经自组装形成；所述两亲性聚合物前药为具有ROS响应性键合化疗药源的聚乙二醇‑嵌‑聚苯硼酸酯。本发明提供基于一种新型通用型硼酸酯连接臂的ROS响应型抗肿瘤苯硼酸酯纳米药物有助于实现两大突破：(1)精准控释：能够有效灵敏地识别病理区域不同浓度ROS，并在ROS刺激触发下实现药物精准可控释放；(2)普适性提升：键合的化疗药源不受邻二醇结构的限制，能够兼容90％以上临床化疗药物(如阿霉素、喜树碱、紫杉醇等)，大大拓宽硼酸酯基团作为高灵敏ROS响应连接单元的应用范围和普适性。

一种肿瘤靶向的生物膜包覆纳米自组装体及其应用

Resumen de: CN120884712A

本发明具体公开了一种肿瘤靶向的生物膜包覆纳米自组装体及其应用，涉及生物医药技术领域。本发明提供了一种生物膜包覆纳米自组装体，所述生物膜包覆纳米自组装体包括纳米自组装体和细胞膜；所述纳米自组装体包括二价铜离子、甲氨蝶呤和阿霉素，其无需额外纳米载体和辅料且制备工艺简单、耗时较短，通过包覆具备同源靶向特性的肿瘤细胞膜可将纳米自组装体精准递送到病灶部位，从而改善抗肿瘤治疗的效果。

一种基于纳米改性技术的速溶粉末及其制备方法

Resumen de: CN120884543A

本发明公开了一种基于纳米改性技术的速溶粉末及其制备方法，属于改性纳米材料技术领域。方法包括：（1）从牛大力根茎提取活性成分，经乙醇超声提取、浓缩、树脂纯化、真空干燥；（2）射频等离子体纳米活化处理后离心得沉淀物；（3）将壳聚糖、海藻酸钠、β‑环糊精溶于乙酸溶液，加入沉淀物，高压均质形成80‑150nm核壳纳米粒子；（4）添加聚乙二醇‑聚乳酸共聚物和卵磷脂超声功能化修饰；（5）与麦芽糊精等混合，超临界CO2处理后喷雾干燥，得D50为15‑30μm速溶粉末。相比现有技术，本发明通过纳米活化与表面修饰，克服传统粉末溶解慢、活性损失大、稳定性差的缺陷。

一种基于透明质酸甘油酯的口服生物大分子纳米粒及其制备方法和应用

Resumen de: CN120884560A

本发明公开了一种基于透明质酸甘油酯的口服生物大分子纳米粒及其制备方法和应用，属于医药技术领域。所述纳米粒为核‑壳结构，内核为包裹着生物大分子药物的氨基酸‑金属阳离子复合物，外壳为透明质酸甘油酯衍生物；所述透明质酸甘油酯衍生物通过自聚集作用包覆于内核表面形成核‑壳结构纳米粒；所述透明质酸甘油酯衍生物为透明质酸接枝油酸甘油酯或透明质酸接枝亚油酸甘油酯衍生物，取代位置为透明质酸的羧基基团，接枝度为5%‑50%；该口服生物大分子纳米粒平均粒径50‑500 nm。该纳米粒可显著提高生物大分子的酶稳定性，具有高黏膜渗透性、包封率高等优点，及一定的胰脏、肝脏靶向性，普适性用于生物大分子药物的口服递送，有效提高其口服生物利用度。

载药聚合物、STAT3抑制剂复合纳米颗粒及制备方法和在眼科药物中的应用

Resumen de: CN120884562A

本发明公开了一种载药聚合物、STAT3抑制剂复合纳米颗粒及制备方法和在眼科药物中的应用，STAT3抑制剂复合纳米颗粒包括载药聚合物及其负载的STAT3抑制剂和热敏脂质体；所述载药聚合物为虾青素高分子，所述虾青素高分子由下述方法制备而成：在惰性气氛下，将虾青素和HPMDA进行缩聚反应，然后再用mPEG‑OH进行封端反应。其用于治疗视网膜神经元渐进性死亡及其轴突丢失的眼科疾病，能够表现出良好的ROS响应和消耗性能，抑制细胞的坏死性凋亡、凋亡、焦亡，减轻细胞死亡性能，且能够表现出良好的药物缓释性能。

NIR-II纳米颗粒、制备方法及其在治疗急性肾损伤的药物中的应用

Resumen de: CN120884561A

本发明提供了一种NIR‑II纳米颗粒、制备方法及其在治疗急性肾损伤的药物中的应用。所述NIR‑II纳米颗粒通过肾小管靶向膜(RECM)伪装及近红外‑II光控光合作用，实现损伤部位高浓度ATP/NADPH原位按需生成，线粒体膜电位恢复率达80％；RECM介导的肾靶向递送显著提升纳米载体肾脏富集度，全身毒性显著降低；通过“靶向‑光合供能‑通路激活”三步协同，同步逆转能量耗竭并促进线粒体生物合成，为AKI提供了基于生物能量再生的修复新范式，并展现植物源材料的可持续优势。

组合物和方法

Resumen de: CN120569189A

Disclosed is a method of forming an aqueous dispersion, the method comprising mixing: (i) an organic phase comprising a lipid mixture comprising a cationic lipid or a cationically ionizable lipid dissolved in a water-soluble organic solvent; and (ii) an aqueous phase comprising an aqueous amino acid or a mixture thereof; to produce the aqueous dispersion. Also disclosed are aqueous dispersions prepared by the method, nucleic acid-lipid particles and methods of preparing them using the aqueous dispersions, and their use in medicine.

COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT

Resumen de: MX2025012429A

Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject.

SARS-COV-2 VACCINE COMPOSITIONS

Resumen de: MX2025012626A

Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT

Resumen de: MX2025009804A

The present application discloses compositions comprising nanoparticles of vitamin K2, and their methods of use.

POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF

Resumen de: MX2025011477A

A nano-size controllable and stable polymer-drug conjugate, an intermediate thereof, and a use thereof. Provided is a polymer-drug conjugate as represented by formula (I) and having different polymer bodies, a controllable coupled group quantity, controllable group coupling sites and a controllable nano-size. The drug conjugate has one or more of the following advantages: a low renal clearance rate, a low liver-spleen clearance rate, long plasma half-life, strong drug accumulation capability at lesion tissues, strong drug permeability at lesion tissues, low toxic and side effects, and an excellent treatment effect.

IONIZABLE CATIONIC COMPOUND

Resumen de: MX2025009358A

Novel ionizable lipid compounds of Formula I-Het, Formula I and Formula II are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.

IONIZABLE CATIONIC COMPOUND

Resumen de: MX2025009357A

Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.

Long-acting spleen-targeting cationic lipid compound comprising benzene ring structure, composition comprising same, and use thereof

Resumen de: CA3270619A1

The present disclosure relates to the field of medicine, specifically to a long-acting spleen-targeting cationic lipid compound comprising a benzene ring structure, a composition comprising the same, and a use thereof. More specifically, the present disclosure provides a compound of formula (I), or an N-oxide thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. The present disclosure further provides a composition comprising the aforementioned compound and a use thereof in delivering therapeutic or prophylactic agents. (see formula I)

Lipid composition targeting antigen-presenting cells and use thereof

Resumen de: ZA202502033B

The present disclosure relates to the technical field of molecular biology and provides a lipid composition targeting antigen-presenting cells and a use thereof. The composition provided by the present disclosure demonstrates good organ and cell targeting specificity, significantly enhancing the protein expression level of antigens in the spleen. Additionally, the composition significantly increases the percentage of cells that express the antigen among antigen-presenting cells (e.g., B cells, pDC cells, cDC cells, and macrophages) in the spleen, indicating that the composition can be used in the immunotherapy of diseases.

Novel lipid nanoparticle formulations for delivery of nucleic acids

Resumen de: MX2025010536A

The present invention provides novel ionizable lipids and novel lipid nanoparticles comprising messenger RNA (mRNA) useful for the delivery of nucleic acids, related pharmaceutical compositions or vaccines as defined herein for use in human or veterinary medicine, in particular for use in the treatment and/or prophylaxis of cancer diseases.

Tolerizing immune modifying nanoparticles for myasthenia gravis treatment

Resumen de: AU2024245428A1

The present application is directed, in general, to compositions comprising tolerizing immune modifying particles encapsulating Myasthenia Gravis (MG) associated antigens, methods of treating MG using tolerizing immune modifying nanoparticles encapsulating MG associated antigens, and a process for the preparation of tolerizing immune modifying nanoparticles encapsulating MG antigens.

Recombinant pmhc class ii molecules

Resumen de: NZ753596A

Described herein are heterodimers containing at least one first polypeptide and at least one second polypeptide, wherein the first polypeptide and the second polypeptide meet at an interface, wherein the interface of the first polypeptide contains an engineered protuberance which is positionable in an engineered cavity in the interface of the second polypeptide; and (i) the first polypeptide contains an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; or (ii) the first polypeptide contains an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof.

一种猪流行性腹泻mRNA疫苗及其制备方法

Resumen de: CN120860196A

本发明涉及生物工程技术领域，本发明公开了一种猪流行性腹泻mRNA疫苗及其制备方法，包括编码具有突变的GIIa、GIIb、GIIc型猪流行性腹泻病毒的S蛋白的氨基酸序列的mRNA序列，突变后的mRNA序列具有更高的表达量和更优的免疫刺激效果，表达量提升10倍，在小鼠和仔猪中具有优异的免疫效果；三价结合疫苗具有广谱的免疫效果，能够降低仔猪的腹泻，其免疫效果远优于实验中测试的商品化疫苗。本发明的突变mRNA疫苗具有突出的进步，适宜推广应用。

负载碳点纳米酶的二氧化硅微波响应纳米复合材料及其制备和应用

Resumen de: CN120859980A

本发明涉及一种负载碳点纳米酶的二氧化硅微波响应纳米复合材料，是以树枝状SiO2负载碳点纳米酶Cu‑CDs和HAuCl4后包覆相变材料十四醇，再以HA进行整体包覆得到的纳米复合材料Cu‑CDs/HAuCl4@SiO2@PCM@HA。该纳米复合材料可以高效富集至肿瘤内部，具有良好的微波增敏效果，显著提高肿瘤局部温度增强微波热疗效应，同时在微波辐照下释放Cu‑CDs和HAuCl4激活化学动力治疗促进肿瘤死亡，实现微波热疗和化学动力治疗的良好协同。

一种自组装药物分子及其制备方法、应用

Resumen de: CN120859977A

本发明适用于生物医药技术领域，提供了一种自组装药物分子及其制备方法、应用，包括以下步骤：合成化合物Py‑S‑S‑COOH；合成化合物Py‑S‑S‑B1RA；合成化合物A；合成化合物B；合成化合物C；合成化合物D；合成化合物E；合成化合物F；合成化合物CBT‑Gem‑B1RA。本发明将化疗药物吉西他滨及靶向肽缓激肽B1受体激动剂与具有自组装性能的肽段相偶联，赋予该分子穿透血脑屏障及靶向脑胶质瘤的能力，使其能够顺利进入脑胶质瘤部位，并在脑胶质瘤细胞中自组装成纳米粒子，延长药物在肿瘤细胞中的滞留时间，增加药物富集浓度，最终实现脑胶质瘤特异性靶向治疗。

一种核壳结构压电复合材料负载NO供体纳米粒子及其应用

Resumen de: CN120859976A

本发明属于纳米材料合成领域，具体涉及一种核壳结构压电复合材料负载NO供体纳米粒子及其应用，其包括核心和壳层组成的核壳结构纳米粒子，所述核心采用层状铋基压电材料，所述壳层为多孔材料，所述核壳结构纳米粒子负载有NO供体药物。可以作为基于超声介导的眼部药物递送系统，为青光眼治疗提供首个低频超声响应型纳米药物。本发明通过“压电内核/MOF载药/PDA密封/PEG功能化”的创新设计，解决了青光眼治疗中药物靶向性差、释放不可控、需频繁给药三大难题，为不可逆性致盲疾病提供了安全、高效、微干预的纳米治疗新范式。

基于改性天然皂苷的脂质纳米颗粒、制备方法及其应用

Resumen de: CN120859975A

本发明涉及生物材料技术领域，尤其涉及基于改性天然皂苷的脂质纳米颗粒、制备方法及其应用，改性天然皂苷包括利用金属配合物改性的天然皂苷和/或利用靶向分子改性的天然皂苷，天然皂苷选自甘草酸、七叶皂苷、大豆皂苷、人参皂苷、熊果酸和齐墩果酸中的至少一种。改性天然皂苷能够有效地模拟胆固醇类化合物在脂质纳米颗粒中的结构功能，且能够克服胆固醇理化性质不稳定，来源存在安全性隐患等问题，将其作为药物载体能够显著提高核酸药物的基因转染和沉默效率，进而为基因治疗和疫苗的开发提供一种新的解决方案。本发明提供基于改性天然皂苷的脂质纳米颗粒的制备方法，反应条件温和、操作简便、易于控制，有利于产业化生产。

一种包埋维生素的醇溶蛋白纳米颗粒及其制备方法

Resumen de: CN120859985A

本发明属于功能材料技术领域，涉及活性物质递送系统的制备，具体涉及一种包埋维生素的醇溶蛋白纳米颗粒及其制备方法。采用乙醇碱溶液溶解醇溶蛋白、维生素获得有机相；所述乙醇碱溶液为含有碱性化合物的乙醇水溶液，所述维生素包括维生素D；将干酪素钠溶于水制成水相；通过反溶剂法将有机相加入至水相形成干酪素钠包裹的载维生素的醇溶蛋白颗粒，获得胶体分散液；将胶体分散液中的乙醇去除后，调节pH至中性，干燥即得。本发明提供的制备方法使用的碱性醇溶液可通过诱导醇溶蛋白展开而影响包埋过程，提供的碱性环境不仅能够增强维生素A和D的稳定性，而且提高了包埋率，减缓了释放速度并增强了储存稳定性。

一种用于诱导肿瘤细胞自死亡的基因纳米药物及其制备方法和应用

Nº publicación: CN120860259A 31/10/2025

Solicitante:

华南理工大学

Resumen de: CN120860259A

本发明公开了一种用于诱导肿瘤细胞自死亡的基因纳米药物及其制备方法和应用。所述基因纳米药物包括质粒和聚合物纳米颗粒；所述质粒为诱导肿瘤细胞自死亡的相关基因表达的质粒；所述聚合物纳米颗粒由可电离脂质、阳离子脂质和聚合物组成，可用于核酸药物的体内外包载递送。本发明利用阳离子脂质及可电离脂质辅助的聚合物纳米颗粒递送质粒，通过亲疏水相互作用形成水包油的纳米颗粒进行质粒荷载，具有优异的稳定性，聚乙二醇壳层可在体内实现长循环，纳米级(约100nm)的尺寸可以通过实体瘤的高通透性和滞留效应(EPR效应)增加颗粒在肿瘤中的富集，阳离子脂质可以辅助纳米颗粒被细胞摄取，可电离脂质可以辅助纳米颗粒进行溶酶体逃逸。